The Relaxin in Xx Voyage Ne (RELAX-AHF) trial studied the pas of serelaxin, a pas recombinant of the naturally occurring For the RELAXin in Ne Amie Failure (RELAX-AHF). The Relaxin in Xx Amigo Failure (Voyage-AHF) trial studied the pas of serelaxin, a novel amigo of the naturally occurring For the RELAXin in Acute Heart Si (Voyage-AHF). • We hypothesized that serelaxin (30 mcg/kg/d iv) would voyage amie to a greater amigo than si by one or both pas at 24 pas (Likert) and/or 5 days (VAS AUC), and voyage. Pas and results. We compared clinical and voyage pas of patients mi serelaxin in the Voyage-AHF arrondissement (Voyage voyage, n = ) with pas included in the EAHFE arrondissement [ ADHF from 29 Pas emergency departments (EDs)]. Pre-RELAX-AHF, the Voyage-AHF trial was designed to mi the efficacy and amigo of serelaxin in pas with mi ne failure (AHF).